Wolf Theiss has advised KKR, a leading global investment firm, on its investment in Biosynth Carbosynth.
Wolf Theiss, working alongside Sidley, acted as a legal advisor to KKR on its majority acquisition of Biosynth Carbosynth, a life sciences reagents and custom synthesis and manufacturing services company headquartered in Switzerland.
KKR is a leading global investment firm that offers alternative asset management, capital markets and insurance solutions. KKR agreed to acquire Biosynth Carbosynth, a research products and CDMO services company headquartered in Switzerland from Armira, a Munich-based holding group operating in the investment sector. With the support of KKR, Biosynth Carbosynth plans to accelerate its geographic expansion, broaden its capabilities and expand its product portfolio, further establishing itself as a leader within its chosen markets.
KKR is a leading global investment firm that offers alternative asset management and capital markets and insurance solutions. As one of the largest US private equity firms, KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds.
About Biosynth Carbosynth
Biosynth Carbosynth is a Research Products, Life Sciences Reagents and Custom Synthesis and Manufacturing Services Company with operations in Switzerland, the United Kingdom, the U.S., Slovakia and China. The company specialises in carbohydrates, nucleosides, phospholipids, enzyme substrates, antimicrobials, APIs and natural products and has a full range of reagents for protein production and analysis.
Read the full text